P53 function influences the effect of fractionated radiotherapy on glioblastoma tumors

International Journal of Radiation Oncology Biology Physics

Volumn 43, Issue 2, 1999, Pages 399-403

  Haas Kogan, Daphne A ^a   Kogan, Scott S ^a   Yount, Garret ^a   Hsu, Jennie ^a   Haas, Martin ^b   Deen, Dennis F ^a   Israel, Mark A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell cycle; Fractionation; Glioblastoma; P53; Radiotherapy

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ARTICLE; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BRAIN NEOPLASMS; CELL CYCLE; CELL SURVIVAL; DOSE FRACTIONATION; GENES, P53; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; RADIATION TOLERANCE; RETROVIRIDAE; TUMOR CELLS, CULTURED;

EID: 0033556646     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00393-9     Document Type: Article

References (20)

1. Leibel S.A., Sheline G.E. Radiation therapy for neoplasms of the brain. J Neurosurg. 66:1987;1-22.
2. Halperin E.C. Multiple-fraction-per-day external beam radiotherapy for adults with supratentorial malignant gliomas. J Neurooncol. 14:1992;255-262.
3. Hall EJ, ed. Radiobiology for the radiologist. 4th ed. Philadelphia: J.B. Lippincott; 1994. p. 138-160.
4. 1 arrest and p53-independent apoptosis influence on the radiobiologic response of glioblastoma. Int J Radiat Oncol Biol Phys. 36:1996;95-103.
5. Yount G.L., Haas-Kogan D.A., Vidair C.A., Haas M., Dewey W.C., Israel M.A. Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer Res. 56:1996;500-506.
6. Hsiao M., Low J., Dorn E., Ku D., Pattengale P., Yeargin J., Haas M. Gain-of-function mutations of the p53 gene induced lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol. 145:1994;702-714.
7. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119:1992;493-501.
8. 1-phase checkpoint. Radiat Res. 145:1996;289-298.
9. Clarke A.R., Purdie C.A., Harrison D.J., Morris R.G., Bird C.C., Hooper M.L., Wyllie A.H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature. 362:1993;849-852.
10. Lotem J., Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood. 82:1993;1092-1096.
11. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993a;74:957-967.
12. Albright N. Computer programs for the analysis of cellular survival data. Radiat Res. 112:1987;331-340.
13. Fertil B., Malaise E.P. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors analysis of 101 published survival curves . Int J Radiat Oncol Biol Phys. 11:1985;1699-1707.
14. Baltuch G.H., de Tribolet N. Role of p53 as a prognostic marker in low-grade (WHO grade II). Crit Rev Neurosurg. 5:1995;103-107.
15. Esrig D., Elmajian D., Groshen S., Freeman J.A., Stein J.P., Chen S.-C., Nichols P.W., Skinner D.G., Jones P.A., Cote R.J. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 331:1994;1259-1264.
16. Biard D.S.F., Martin M., Le Rhun Y., Duthu A., Lefaix J.L., May E., May P. Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res. 54:1994;3361-3364.
17. Bristow R.G., Jang A., Peacock J., Chung S., Benchimol S., Hill R.P. Mutant p53 increases radioresistance in rat embryo fibroblasts simultaneously transfected with HPV16-E7 and/or activated H-ras. Oncogene. 9:1994;1527-1536.
18. Lee J.M., Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA. 90:1993;5742-5746.
19. MacIlwrath A.J., Vasey P.A., Ross G.M., Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines dependence on wild-type p53 for radiosensitivity . Cancer Res. 54:1994;3178-3722.
20. Slichenmyer W.J., Nelson W.G., Slebos R.J., Kastan M.B. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 53:1993;4164-4168.